Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164981 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02164981: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02164981 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02164981, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate whether a single infusion of intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5% dextrose solution) at in treating positive and negative symptoms of schizophrenia
Interventions
- OTHER Placebo
- DRUG sodium nitroprusside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2017-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164981
The ClinicalTrials.gov registry entry for NCT02164981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02164981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164981 about?
NCT02164981 is a clinical study titled "A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia". The primary objective of this study is to investigate whether a single infusion of intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5% dextrose solution) at in treating positive and negative symptoms of schizophrenia
What is the current status of trial NCT02164981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2015-05-01. Estimated completion is 2017-04-05.
What interventions are being tested in trial NCT02164981?
The interventions under investigation include: Placebo (OTHER), sodium nitroprusside (DRUG).
Who is sponsoring clinical trial NCT02164981?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.